Compugen Ltd (CGEN): Operating Income
$31.33M
Year ended 2025-12-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.33M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$14.89M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$12.99M | n/m | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | -$35.37M | n/m | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | -$35.07M | n/m | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | -$31.50M | n/m | 2023-08-23, From 2020-01-01 |
| 2019-12-31 | -$28.88M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$23.23M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$37.41M | n/m | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | -$32.58M | n/m | 2019-03-21, From 2016-01-01 |
| 2015-12-31 | -$20.92M | n/m | 2018-03-27, From 2015-01-01 |
| 2014-12-31 | -$12.34M | n/m | 2017-02-16, From 2014-01-01 |
| 2013-12-31 | -$17.04M | n/m | 2016-03-07, From 2013-01-01 |
| 2012-12-31 | -$13.54M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | -$11.98M | n/m | 2014-02-18, From 2011-01-01 |
| 2010-12-31 | -$7.88M | n/m | 2013-03-21, From 2010-01-01 |
| 2009-12-31 | -$7.63M | n/a | 2012-03-14, From 2009-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Compugen Ltd (CGEN) | 2025-12-31 | $31.33M | n/m |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | -$648.13M | n/m |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | -$270.54M | n/m |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $12.52M | n/m |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$479.33M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$105.97M | n/m |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | -$159.55M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$1.14M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$55.56M | n/m |
Compare CGEN, RXRX, AUTL, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗